Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes
Our findings highlight CD33<sup>+</sup> cell phenotype as a key determinant of response to chemo-immunotherapy, which can be assessed from peripheral blood. This offers a valuable tool in the context of metastatic TNBC, in which tissue sampling is often challenging.
Authors
- Avia D. Wilkerson (ORCID: https://orcid.org/0000-0002-2185-9557)
- Patricia Rayman (ORCID: https://orcid.org/0000-0003-2206-370X)
- Tyler Alban (ORCID: https://orcid.org/0000-0002-3261-140X)
- Zahraa Al‐Hilli (ORCID: https://orcid.org/0000-0003-2383-0499)
- Alberto J. Montero (ORCID: https://orcid.org/0000-0002-8221-8120)
- Jennifer Powers (ORCID: https://orcid.org/0000-0001-8054-518X)
- Salendra Singh (ORCID: https://orcid.org/0000-0002-4903-9868)
- Paul G. Pavicic (ORCID: https://orcid.org/0000-0002-5772-3192)
- Ivan Jurić (ORCID: https://orcid.org/0000-0002-1076-6320)
- C. Marcela Díaz‐Montero (ORCID: https://orcid.org/0000-0002-6941-4215)
- Jennifer S. Ko (ORCID: https://orcid.org/0000-0003-0629-775X)
- Timothy A. Chan (ORCID: https://orcid.org/0000-0002-9265-0283)
- Prerana Bangalore Parthasarathy (ORCID: https://orcid.org/0009-0002-7702-9656)
Institutions
- Cleveland Clinic (US)
- University Hospitals Seidman Cancer Center (US)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-05-17
- DOI
- https://doi.org/10.1038/s43856-025-00860-4
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.87